
William I Sivitz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6141963/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Membrane potentialâ€dependent regulation of mitochondrial complex II by oxaloacetate in interscapular brown adipose tissue. FASEB BioAdvances, 2022, 4, 197-210.	1.3	4
2	A Novel Triphenylphosphonium Carrier to Target Mitochondria without Uncoupling Oxidative Phosphorylation. Journal of Medicinal Chemistry, 2021, 64, 662-676.	2.9	50
3	Effect of mitoquinone on liver metabolism and steatosis in obese and diabetic rats. Pharmacology Research and Perspectives, 2021, 9, e00701.	1.1	7
4	Perilipin 2 downregulation in \hat{l}^2 cells impairs insulin secretion under nutritional stress and damages mitochondria. JCl Insight, 2021, 6, .	2.3	10
5	Insulin and IGF-1 receptors regulate complex l–dependent mitochondrial bioenergetics and supercomplexes via FoxOs in muscle. Journal of Clinical Investigation, 2021, 131, .	3.9	28
6	Simultaneous Quantification of Mitochondrial ATP and Using ATP Methodology. Methods in Molecular Biology, 2021, 2276, 271-283.	0.4	0
7	An Observational Study of the Equivalence of Age and Duration of Diabetes to Glycemic Control Relative to the Risk of Complications in the Combined Cohorts of the DCCT/EDIC Study. Diabetes Care, 2020, 43, 2478-2484.	4.3	19
8	Adipose Triglyceride Lipase Is a Key Lipase for the Mobilization of Lipid Droplets in Human β-Cells and Critical for the Maintenance of Syntaxin 1a Levels in β-Cells. Diabetes, 2020, 69, 1178-1192.	0.3	20
9	Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight. Diabetes Care, 2020, 43, 940-947.	4.3	14
10	Adipose Triglyceride Lipase is a Key Lipase for the Mobilization of Lipid Droplets in Human Beta Cells and Critical for the Maintenance of Syntaxin1a Level in Beta Cells. Diabetes, 2020, , db190951.	0.3	0
11	Effect of mitoquinone (Mito-Q) on neuropathic endpoints in an obese and type 2 diabetic rat model. Free Radical Research, 2020, 54, 311-318.	1.5	19
12	Oxaloacetate Mediates Mitochondrial Metabolism and Function. Current Metabolomics and Systems Biology, 2020, 7, 11-23.	0.6	5
13	Modulation of complex IIâ€energized respiration in muscle, heart, and brown adipose mitochondria by oxaloacetate and complex I electron flow. FASEB Journal, 2019, 33, 11696-11705.	0.2	15
14	Risk Factors for Retinopathy in Type 1 Diabetes: The DCCT/EDIC Study. Diabetes Care, 2019, 42, 875-882.	4.3	114
15	Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care, 2019, 42, 657-664.	4.3	32
16	Response to Comment on Braffett et al. Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care 2019;42:657–664. Diabetes Care, 2019, 42, e137-e137.	4.3	0
17	Oxaloacetic acid mediates ADP-dependent inhibition of mitochondrial complex II–driven respiration. Journal of Biological Chemistry, 2018, 293, 19932-19941.	1.6	30
18	Effect of a mitochondrialâ€ŧargeted coenzyme Q analog on pancreatic βâ€cell function and energetics in high fat fed obese mice. Pharmacology Research and Perspectives, 2018, 6, e00393.	1.1	26

#	Article	IF	CITATIONS
19	Metabolic effects of a mitochondrial-targeted coenzyme Q analog in high fat fed obese mice. Pharmacology Research and Perspectives, 2017, 5, e00301.	1.1	22
20	Regulation of ATP production: dependence on calcium concentration and respiratory state. American Journal of Physiology - Cell Physiology, 2017, 313, C146-C153.	2.1	57
21	Techniques to Investigate Bioenergetics of Mitochondria. Neuromethods, 2017, , 67-94.	0.2	1
22	Impact of Excessive Weight Gain on Cardiovascular Outcomes in Type 1 Diabetes: Results From the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes Care, 2017, 40, 1756-1762.	4.3	77
23	Voltage-Dependent Regulation of Complex II Energized Mitochondrial Oxygen Flux. PLoS ONE, 2016, 11, e0154982.	1.1	13
24	Impaired utilization of membrane potential by complex II-energized mitochondria of obese, diabetic mice assessed using ADP recycling methodology. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2016, 311, R756-R763.	0.9	7
25	Human iPS Cell-Derived Insulin Producing Cells Form Vascularized Organoids under the Kidney Capsules of Diabetic Mice. PLoS ONE, 2015, 10, e0116582.	1.1	48
26	Evidence for metabolic aberrations in asymptomatic persons with type 2 diabetes after initiation of simvastatin therapy. Translational Research, 2015, 166, 176-187.	2.2	4
27	Simultaneous Quantification of Mitochondrial ATP and ROS Production. Methods in Molecular Biology, 2015, 1264, 149-159.	0.4	10
28	Mitochondria and Oxidative Stress in Diabetes. Oxidative Stress in Applied Basic Research and Clinical Practice, 2014, , 63-92.	0.4	0
29	Joiner et al. reply. Nature, 2014, 513, E3-E3.	13.7	9
30	Dietary fat, fatty acid saturation and mitochondrial bioenergetics. Journal of Bioenergetics and Biomembranes, 2014, 46, 33-44.	1.0	41
31	A Mitochondrial-Targeted Coenzyme Q Analog Prevents Weight Gain and Ameliorates Hepatic Dysfunction in High-Fat–Fed Mice. Journal of Pharmacology and Experimental Therapeutics, 2014, 351, 699-708.	1.3	39
32	Mitochondrial Function in Diabetes: Novel Methodology and New Insight. Diabetes, 2013, 62, 1833-1842.	0.3	29
33	Reversibility of Fenofibrate Therapy–Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants. Diabetes Care, 2012, 35, 1008-1014.	4.3	114
34	Peroxisome Proliferator-Activated Receptor γ Decouples Fatty Acid Uptake from Lipid Inhibition of Insulin Signaling in Skeletal Muscle. Molecular Endocrinology, 2012, 26, 977-988.	3.7	21
35	CaMKII determines mitochondrial stress responses in heart. Nature, 2012, 491, 269-273.	13.7	340
36	Bioenergetic Effects of Mitochondrial-Targeted Coenzyme Q Analogs in Endothelial Cells. Journal of Pharmacology and Experimental Therapeutics, 2012, 342, 709-719.	1.3	52

#	Article	IF	CITATIONS
37	Endothelial Cell and Platelet Bioenergetics: Effect of Glucose and Nutrient Composition. PLoS ONE, 2012, 7, e39430.	1.1	36
38	Modifying a high saturated fat diet with omegaâ€3 (nâ€3) polyâ€unsaturated fat improves vascular dysfunction and glucose intolerance. FASEB Journal, 2012, 26, 686.13.	0.2	0
39	Modifying a high fat diet with monoâ€and polyâ€unsaturated fats improves coronary dysfunction. FASEB Journal, 2012, 26, 1055.7.	0.2	Ο
40	Feeding Frequency and Appetite in Lean and Obese Prepubertal Children. Obesity, 2011, 19, 560-567.	1.5	3
41	Mitochondrial superoxide and coenzyme Q in insulin-deficient rats: increased electron leak. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2011, 301, R1616-R1624.	0.9	14
42	Superoxide production by mitochondria of insulin-sensitive tissues: mechanistic differences and effect of early diabetes. Metabolism: Clinical and Experimental, 2010, 59, 247-257.	1.5	21
43	The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ: British Medical Journal, 2010, 340, b4909-b4909.	2.4	807
44	Mitochondrial Dysfunction in Diabetes: From Molecular Mechanisms to Functional Significance and Therapeutic Opportunities. Antioxidants and Redox Signaling, 2010, 12, 537-577.	2.5	600
45	Superoxide and Respiratory Coupling in Mitochondria of Insulin-Deficient Diabetic Rats. Endocrinology, 2009, 150, 46-55.	1.4	64
46	Leptin Gene –2548C/A variants predict risperidone-associated weight gain in children and adolescents. Psychiatric Genetics, 2009, 19, 320-327.	0.6	47
47	Mitochondrial Targeted Coenzyme Q, Superoxide, and Fuel Selectivity in Endothelial Cells. PLoS ONE, 2009, 4, e4250.	1.1	18
48	Endogenous Peroxisome Proliferator-Activated Receptor-Î ³ Augments Fatty Acid Uptake in Oxidative Muscle. Endocrinology, 2008, 149, 5374-5383.	1.4	12
49	Mitochondrial proton leak in obesity-resistant and obesity-prone mice. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 293, R1773-R1780.	0.9	39
50	Ectopic brown adipose tissue in muscle provides a mechanism for differences in risk of metabolic syndrome in mice. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 2366-2371.	3.3	256
51	Obesity impairs vascular relaxation in human subjects: hyperglycemia exaggerates adrenergic vasoconstriction. Journal of Diabetes and Its Complications, 2007, 21, 149-157.	1.2	53
52	Antecedent Hypoglycemia, Catecholamine Depletion, and Subsequent Sympathetic Neural Responses. Endocrinology, 2006, 147, 2781-2788.	1.4	35
53	Reactive Oxygen and Targeted Antioxidant Administration in Endothelial Cell Mitochondria. Journal of Biological Chemistry, 2006, 281, 39766-39775.	1.6	106
54	Respiratory uncoupling by UCP1 and UCP2 and superoxide generation in endothelial cell mitochondria. American Journal of Physiology - Endocrinology and Metabolism, 2005, 288, E71-E79.	1.8	45

#	Article	IF	CITATIONS
55	Scintigraphic Detection of Benign Struma Ovarii in a Hyperthyroid Patient. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3771-3772.	1.8	14
56	Glycation and Carboxymethyllysine Levels in Skin Collagen Predict the Risk of Future 10-Year Progression of Diabetic Retinopathy and Nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications Participants With Type 1 Diabetes. Diabetes, 2005, 54, 3103-3111.	0.3	384
57	Cyclic Changes in Glycemia Assessed by Continuous Glucose Monitoring System During Multiple Complete Menstrual Cycles in Women with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2004, 6, 473-480.	2.4	32
58	Free Fatty Acid-induced β-Cell Defects Are Dependent on Uncoupling Protein 2 Expression. Journal of Biological Chemistry, 2004, 279, 51049-51056.	1.6	179
59	Adiponectin and C-reactive protein in obesity, type 2 diabetes, and monodrug therapy. Metabolism: Clinical and Experimental, 2004, 53, 1454-1461.	1.5	62
60	Understanding insulin resistance. Postgraduate Medicine, 2004, 116, 41-48.	0.9	4
61	Leptin administration to normal rats does not alter catecholamine responsiveness to insulin-induced hypoglycemia. Metabolism: Clinical and Experimental, 2003, 52, 1484-1490.	1.5	3
62	Leptin and Body Fat in Type 2 Diabetes and Monodrug Therapy. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1543-1553.	1.8	40
63	UCP2-dependent Proton Leak in Isolated Mammalian Mitochondria. Journal of Biological Chemistry, 2002, 277, 3918-3925.	1.6	65
64	The Concept of Selective Leptin Resistance: Evidence From Agouti Yellow Obese Mice. Diabetes, 2002, 51, 439-442.	0.3	202
65	Leptin Potentiates Thermogenic Sympathetic Responses to Hypothermia: A Receptor-Mediated Effect. Diabetes, 2002, 51, 2434-2440.	0.3	50
66	Uncoupling Metabolism and Coupling Leptin to Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 881-883.	1.1	14
67	Differential modulation of leptin-induced sympathoexcitation by baroreflex activation. Journal of Hypertension, 2002, 20, 1633-1641.	0.3	39
68	Hemodynamic consequences of neuropeptide Y-induced obesity. American Journal of Hypertension, 2002, 15, 137-142.	1.0	15
69	Leptin interacts with heart rate but not sympathetic nerve traffic in healthy male subjects. Journal of Hypertension, 2001, 19, 1089-1094.	0.3	59
70	Role of Corticotrophin-Releasing Factor in Effects of Leptin on Sympathetic Nerve Activity and Arterial Pressure. Hypertension, 2001, 38, 384-388.	1.3	59
71	Leptin Acts in the Central Nervous System to Produce Dose-Dependent Changes in Arterial Pressure. Hypertension, 2001, 37, 936-942.	1.3	138
72	Lipotoxicity and glucotoxicity in type 2 diabetes. Postgraduate Medicine, 2001, 109, 55-64.	0.9	31

#	Article	IF	CITATIONS
73	Effect of Acute and Antecedent Hypoglycemia on Sympathetic Neural Activity and Catecholamine Responsiveness in Normal Rats. Diabetes, 2001, 50, 1119-1125.	0.3	28
74	Does Leptin Stimulate Nitric Oxide to Oppose the Effects of Sympathetic Activation?. Hypertension, 2001, 38, 1081-1086.	1.3	61
75	Pubertal Adolescent Male-Female Differences in Insulin Sensitivity and Glucose Effectiveness Determined by the One Compartment Minimal Model. Pediatric Research, 2000, 48, 384-388.	1.1	105
76	Fasting and Leptin Modulate Adipose and Muscle Uncoupling Protein: Divergent Effects Between Messenger Ribonucleic Acid and Protein Expression1. Endocrinology, 1999, 140, 1511-1519.	1.4	101
77	Interactions Between the Melanocortin System and Leptin in Control of Sympathetic Nerve Traffic. Hypertension, 1999, 33, 542-547.	1.3	349
78	Heritability of plasma leptin levels. Journal of Hypertension, 1999, 17, 27-31.	0.3	51
79	Plasma leptin in diabetic and insulin-treated diabetic and normal rats. Metabolism: Clinical and Experimental, 1998, 47, 584-591.	1.5	61
80	Effects of Leptin on Insulin Sensitivity in Normal Rats*. Endocrinology, 1997, 138, 3395-3401.	1.4	234
81	Sympathetic and Cardiorenal Actions of Leptin. Hypertension, 1997, 30, 619-623.	1.3	276
82	Effect of Maternal Diabetes upon Fetal Rat Myocardial and Skeletal Muscle Glucose Transporters1. Pediatric Research, 1997, 41, 11-19.	1.1	40
83	Rat Adipose ob mRNA Levels in States of Altered Circulating Glucose and Insulin. Biochemical and Biophysical Research Communications, 1996, 220, 520-525.	1.0	33
84	Time-dependent regulation of rat adipose tissue glucose transporter (GLUT4) mRNA and protein by insulin in streptozocin-diabetic and normal rats. Metabolism: Clinical and Experimental, 1992, 41, 1267-1272.	1.5	12
85	Mammalian Glucose Transporters: Structure and Molecular Regulation. , 1991, 47, 349-388.		66
86	Assessment of Glucose Transporter Gene Expression Using the Polymerase Chain Reaction. Endocrinology, 1991, 128, 2387-2394.	1.4	18
87	Regulation of the Glucose Transporter in Animal Models of Diabetes. Advances in Experimental Medicine and Biology, 1991, 293, 249-262.	0.8	4
88	Regulation of Glucose Transporter Messenger RNA Levels in Rat Adipose Tissue by Insulin. Molecular Endocrinology, 1990, 4, 583-588.	3.7	40
89	Computer-Assisted Instruction in Intense Insulin Therapy Using a Mathematical Model for Clinical Simulation With a Clinical Algorithm and Flow Sheet. The Diabetes Educator, 1989, 15, 77-79.	2.6	26
90	Regulation of the Glucose Transporter in Developing Rat Brain*. Endocrinology, 1989, 124, 1875-1880.	1.4	77

#	Article	IF	CITATIONS
91	Regulation of glucose transporter messenger RNA in insulin-deficient states. Nature, 1989, 340, 72-74.	13.7	247
92	Case Report: Renal Hypophosphatemic Osteomalacia Unmasked by Hyperthyroidism. American Journal of the Medical Sciences, 1986, 292, 231-234.	0.4	1
93	Cellular Mechanisms of Insulin Release: The Effects of Vitamin D Deficiency and Repletion on Rat Insulin Secretion*. Endocrinology, 1983, 113, 1511-1518.	1.4	175